Distinguished in Lymphadenectomy

Dr. Jason D. Wright

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Trustees Of Columbia University In The City Of New York
51 W 51st St, Fl 3 Suite 360, 
New York, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Distinguished in Lymphadenectomy
Trustees Of Columbia University In The City Of New York
51 W 51st St, Fl 3 Suite 360, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jason Wright is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Wright is rated as a Distinguished provider by MediFind in Lymphadenectomy. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hysterectomy, and Oophorectomy.

His clinical research consists of co-authoring 728 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Lymphadenectomy.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
51 W 51st St, Fl 3 Suite 360, New York, NY 10019

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer
A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Procedure
Study Drug: Abemaciclib
Study Phase: Phase 1
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other
Study Phase: Not Applicable
The Impact of Vaginal Dilator Therapy on Pain Scores and Sexual Function Among Women With Gynecologic and Breast Cancers Experiencing Dyspareunia: a Randomized Controlled Trial
The Impact of Vaginal Dilator Therapy on Pain Scores and Sexual Function Among Women With Gynecologic and Breast Cancers Experiencing Dyspareunia: a Randomized Controlled Trial
Enrollment Status: Withdrawn
Publish Date: April 04, 2024
Intervention Type: Other, Device
Study Phase: Not Applicable
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drugs: Abemaciclib, Letrozole
Study Phase: Phase 2
The nCYT Study: A Powered Study to Evaluate the Sensitivity and Specificity of Cytological Evaluation of Fallopian Tube Samples Collected by the Cytuity in Determining the Presence of Malignancy
The nCYT Study: A Powered Study to Evaluate the Sensitivity and Specificity of Cytological Evaluation of Fallopian Tube Samples Collected by the Cytuity in Determining the Presence of Malignancy
Enrollment Status: Completed
Publish Date: January 20, 2021
Intervention Type: Device
View 7 Less Clinical Trials

727 Total Publications

Physician Peer Influence on Salpingectomy Uptake for Tubal Sterilization and Ovarian Cancer Prevention.
Physician Peer Influence on Salpingectomy Uptake for Tubal Sterilization and Ovarian Cancer Prevention.
Journal: JAMA network open
Published: September 22, 2025
Similar Doctors
Mario M. Leitao
Distinguished in Lymphadenectomy
Dr. Mario M. Leitao
Gynecologic Oncology | Oncology
Distinguished in Lymphadenectomy
Dr. Mario M. Leitao
Gynecologic Oncology | Oncology

Mskcc Surgery Group

160 E 53rd St, 
New York, NY 
 (0.6 miles away)
212-610-0496
Languages Spoken:
English, Portuguese, Spanish
See accepted insurances
Accepting New Patients

Mario Leitao is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Leitao is rated as an Elite provider by MediFind in Lymphadenectomy. His top areas of expertise are Endometrial Cancer, Vulvar Cancer, Vaginal Cancer, Hysterectomy, and Lymphadenectomy. Dr. Leitao is currently accepting new patients.

Distinguished in Lymphadenectomy
Dr. Nadeem R. Abu-Rustum
Gynecologic Oncology | Oncology
Distinguished in Lymphadenectomy
Dr. Nadeem R. Abu-Rustum
Gynecologic Oncology | Oncology

Mskcc Surgery Group

160 E 53rd St, 
New York, NY 
 (0.6 miles away)
212-610-0496
Languages Spoken:
English
See accepted insurances

Nadeem Abu-Rustum is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Abu-Rustum is rated as an Elite provider by MediFind in Lymphadenectomy. His top areas of expertise are Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Hysterectomy, and Lymphadenectomy.

Advanced in Lymphadenectomy
Dr. Vance A. Broach
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Lymphadenectomy
Dr. Vance A. Broach
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Mskcc Regional Network

650 Commack Rd, 
Commack, NY 
 (36.1 miles away)
631-623-4034
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vance Broach is a Gynecologic Oncologist and an Oncologist in Commack, New York. Dr. Broach has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in Lymphadenectomy. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Vaginal Cancer, Lymphadenectomy, and Splenectomy. Dr. Broach is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wright's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 24 Advanced Conditions
View All 58 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile